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Background: Adjuvant therapy increases disease-free survival in endometrial cancer (EC), but has no impact on overall survival
and negatively influences the quality of life. We investigated the discriminatory power of classical and immunological predictors of
recurrence in a cohort of EC patients and confirmed the findings in an independent validation cohort.
Methods:We reanalysed the data from 355 EC patients and tested our findings in an independent validation cohort of 72 patients
with EC. Predictors were selected and Harrell’s C-index for concordance was used to determine discriminatory power for disease-
free survival in the total group and stratified for histological subtype.
Results: Predictors for recurrence were FIGO stage, lymphovascular space invasion and numbers of cytotoxic and memory T-cells.
For high risk cancer, cytotoxic or memory T-cells predicted recurrence as well as a combination of FIGO stage and lymphovascular
space invasion (C-index 0.67 and 0.71 vs 0.70). Recurrence was best predicted when FIGO stage, lymphovascular space invasion
and numbers of cytotoxic cells were used in combination (C-index 0.82). Findings were confirmed in the validation cohort.
Conclusions: In high-risk EC, clinicopathological or immunological variables can predict regional or distant recurrence with equal
accuracy, but the use of these variables in combination is more powerful.
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Endometrial cancer (EC) is the most common gynaecological
cancer in the western world, with yearly over 8500 new cases in the
UK alone (Cancer Research UK, 2014). A distinction can be made
between low- and high-risk EC based on histological parameters
(Bokhman, 1983; Hecht and Mutter, 2006; Evans et al, 2011). Low-
risk EC comprises grade 1–2 endometrioid neoplasms and is most
common. High-risk EC includes non-endometrioid and high-grade
endometrioid neoplasms. Although high-risk EC accounts for just
10% of new cases, it is responsible for more than 40% of deaths
from EC (Amant et al, 2005; Evans et al, 2011; Boll et al, 2012).
Molecular studies describe distinct molecular pathways involved in
pathogenesis and suggest that low and high-risk EC are
manifestations of two different diseases (Lax, 2007; Samarnthai
et al, 2010; Matias-Guiu and Prat, 2013).
There is a clear need to better predict recurrence and disease-
free survival (DFS) in order to optimise patient-tailored treatment,
especially in high-risk EC. The mainstay of treatment is
hysterectomy and bilateral salpingo-oophorectomy (Amant et al,
2005; Wright et al, 2012) with or without pelvic and para-aortic
lymphadenectomy. Adjuvant radiotherapy is advised depending on
age, depth of myometrial invasion, tumour grade and the presence
of lymphovascular space involvement (LVSI) (Creutzberg et al,
2000; ASTEC study group et al, 2009; Nout et al, 2010; Kong et al,
2012; Salvesen et al, 2012; Wright et al, 2012). This reduces
locoregional recurrence from 15 to 5% but has no impact on
overall survival and is associated with considerable toxicity in a
substantial proportion of patients. For patients with advanced and/
or high-grade disease, chemotherapy reduces recurrence outside
the pelvis by 5%, but has no effect on survival (Johnson et al, 2011).
Many studies show a relationship between tumour-infiltrating
lymphocytes (TILs) and cancer behaviour (Kondratiev et al, 2004;
Chang et al, 2005; Galon et al, 2006; de Jong et al, 2009; Leffers
et al, 2009; Gooden et al, 2011; Schreiber et al, 2011; Vesely et al,
2011). In a cohort of 90 EC patients, Kondratiev et al (2004)
described that low numbers of cytotoxic T cells (CTLs) was
related to poor prognosis (hazard ratio (HR) 2.79). A favourable
effect of high numbers of CTLs on progression-free and overall
survival in EC patients was confirmed by staining for CD8-positive
cells with a HR for survival of 0.48 (95% confidence interval
0.26–0.89) (de Jong et al, 2009). de Jong et al (2009) also described
a strong relation with recurrence for the ratio between
CD8-positive cytotoxic T cells and FoxP3-positive regulatory
T cells with a HR of 0.44 (95% confidence interval 0.23–0.84). The
downregulated expression of classical major histocompatibility
complex class I by EC cells also correlates with the risk of
recurrence (Bijen et al, 2010).
In colorectal cancer, an immune score based on TILs has been
shown to better predict recurrence compared with standard TNM
classification (Galon et al, 2006; Pages et al, 2009; Bindea et al,
2011; Fridman et al, 2011; Mlecnik et al, 2011). The use of TILs as a
predictor of colorectal cancer, together with an already established
relation of TIL with disease course, has prompted us to investigate
these immunological variables and their value in predicting EC
recurrence. We examined this possibility by re-analysing existing
data and validated our findings in an independent cohort of high-
risk EC patients.
PATIENTS AND METHODS
Patients. For this study, a new analysis was performed on data
pooled from two previous studies (de Jong et al, 2009; Bijen et al,
2010). This initial study cohort comprised a consecutive series of
355 EC patients treated at a single institution in the Netherlands
between 1984 and 2004 (de Jong et al, 2009; Bijen et al, 2010).
Patients with a previous malignancy or radiotherapy prior to
surgery were excluded. Patients received standard care, undergoing
hysterectomy followed by adjuvant radiotherapy as stipulated by
local and international guidelines. (Creutzberg et al, 2000; ASTEC
study group et al, 2009; Nout et al, 2010; Kong et al, 2012;
Oncoline, 2014). Sections were reviewed by an experienced
Gynaecologic Pathologist (HH) and classified according to the
WHO criteria. Low-risk EC was defined as grade 1–2 endometrioid
cancer. High-risk EC was defined as grade 3 or undifferentiated
endometrioid cancer or non-endometrioid cancer. Owing to the
retrospective character of this study, staging according to
FIGO 1988 classification was used. Follow-up visits were
performed for a period of 5 years, in accordance with local
practice. During each follow-up visit, clinical history was updated
and a physical examination was performed. Data were accrued
until September 2011 and entered into a password-protected
database. Patient identity was protected by study specific patient
numbers. According to Dutch legislation, no further approval by
an Institutional Review Board approval was necessary.
Our validation cohort comprised an international series of 106
high-risk patients selected for grade 3 with deep invasion,
advanced stage or serous or clear cell EC. These patients were
included from 1985 to 2013 and underwent treatment in
Manchester (UK), London (UK), Villejuif (FR), Leiden (NL) and
Groningen (NL), and were selected as a pilot series in the
international TransPORTEC collaboration (Stelloo et al, 2015). To
avoid overlapping cases across the two study cohorts, patients from
the Groningen centre were excluded, leaving 72 cases for the
validation cohort. Clinical follow-up was accrued on all patients in
the validation cohort until September 2014.
Immunohistochemistry. Details of the staining procedure and the
antibodies used in the initial study cohort were described
previously (de Jong et al, 2009, Bijen et al, 2010). In brief, tissue
microarrays were constructed by transferring three core biopsies of
0.6mm diameter from representative areas of tumour centre to a
pre-defined location in a recipient paraffin block. Sections of 4 mm
were cut from these blocks and stained using the antibodies
summarised in Supplementary Table 1. CD8 was used as a marker
for cytotoxic T cells, CD45R0 as a marker for memory T cells and
FoxP3 as a marker for regulatory T cells. Major histocompatibility
complex class 1 expression was stained using antibodies for a wide
range of major histocompatibility complex class 1 heavy chains.
Antigen–antibody reactions for FoxP3 was visualised with
NovaRED (Vector Laboratories, Burlingame, CA, USA) and with
3,30-diaminobenzidine in all other cases. Tumours were evaluated
if more than 20% of at least two cores consisted of tumour
material. Slides were scored by two independent observers, blinded
for patient characteristics and outcome. Discrepancies were
resolved by consensus. Tumour-infiltrating cells per core were
counted and findings were dichotomised using the median as a
cut-off. We choose to use the median because an optimal threshold
is unknown. In studies on prediction of recurrence in colorectal
cancer, the median was also used as a cut-off (Galon et al, 2006;
Pages et al, 2009; Bindea et al, 2011; Fridman et al, 2011; Mlecnik
et al, 2011). As for the ratio of cytotoxic/regulatory T-cells, there is
also no consensus on an optimal threshold. In a previous study, the
median value for the ratio showed a strong relation with survival
and we therefore maintained the median as a cut-off (de Jong et al,
2009). In line with previous publications, CD45ROþ cells were
classified as either present or not present. For scoring of HLA
expression a semiquantative scale as described in literature was
used to categorise expression into normal, partial loss or loss of
expression (Rolland et al, 2007; Bijen et al, 2010). Tissue
microarrays have been used in previous histological studies on
EC. Fons et al (2007) showed a high concordance for protein
expression with full slide sections. Concordance for immunological
markers was also evaluated for the previous to the study by de Jong
et al (2009).
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For the validation cohort, tissue microarrays were constructed
in a similar manner. Sections used for staining CD8 were
pre-treated with Ultra CC1 for 52min at 95 1C. Staining for
CD45R0 and CD8 was performed automatically with Ventana
BenchMark ULTRA IHC/ISH Staining Module according to the
manufacturer’s instructions (Ventana Medical Systems Inc., Roche
Group, Tucson, AZ, USA). Scoring was again carried out by
two independent observers, blinded for patient characteristics.
Discrepancies were resolved by consensus. Examples of staining for
CTLs are shown in Figure 1.
Statistical analysis. Disease-free survival (DFS) was defined as
time until regional or distant recurrence. Local recurrence was not
considered an event because radiotherapy reduces the local
recurrence rate and the indication for radiotherapy is based upon
clinicopathological parameters. Disease-specific survival (DSS) was
defined as time until death of disease. Although DFS was the main
objective in this analysis, we also performed an analysis on DSS for
comparison. Because not all cores were suitable for scoring,
missing values for immunological variables varied between 14.4
and 19.2%. Therefore, missing values for all immunological
variables were imputed based on correlation structure. Myometrial
invasion, FIGO stage, LVSI, nodal status, tumour grade,
histological type, age and immunological variables were used as
predictors (five imputations). To assess the impact of the
imputations on the results, the analysis was also carried out on
the complete cases.
To analyse relations between clinicopathological and immuno-
logical variables, Chi-square tests or Fishers’ exact tests were used.
For survival analysis, log rank test and Cox regression analysis were
performed. To identify predictors for DFS, variables were selected
if these had a previously reported relationship with disease
course. The following variables were considered: age, FIGO stage,
LVSI, myometrial invasion, grade, histological type, HLA-class 1
expression, presence of CD45R0þ cells, high/low numbers of
CD8þ cells and high/low ratio CD8þ /Foxp3þ cells. Survival
analysis was performed and HRs with a 95% confidence interval
were estimated. Predictors for further analysis were selected from
the candidate predictors through backward elimination. To this
end, a multivariate Cox regression analysis for DFS was performed
using all candidate predictors. The least significant variable was left
out in the subsequent Cox regression analysis, and the analysis was
repeated until only significant variables remained (Po0.05).
Backward selection was performed to build a model including
only clinicopathological variables, as well as a model including only
immunological variables, as well as a model combining both
groups of variables. These analyses were performed with SPSS (v20,
IBM statistics, Chicago, IL, USA).
To assess the discriminatory power of the three models,
Harrell’s concordance index (C-index) (Harrell et al, 1996) was
calculated for each model, using STATA (v 11, Statacorp LP,
College Station, TX, USA). This was calculated for the entire
cohort and separately for low/high-risk EC as well as for
endometrioid/non-endometrioid and low(1–2)/high(3)-grade sub-
groups. A C-index close to 0.5 indicates low predictive power and a
C-index closer to 1.0 indicates increasing discriminatory power. In
the final step, the three models were applied to the validation
cohort and again the C-index was calculated.
RESULTS
Baseline characteristics, stratified for low/high-risk EC, are shown
in Table 1. The distribution of variables in the imputed dataset was
not different from the original cohort dataset. The relative
efficiency of imputation for both cohorts varied between 0.97
and 1.00, indicating that more imputations would not contribute to
a more reliable analysis. Median follow-up time was 6.0 years for
the initial study cohort and 2.2 years for the validation cohort.
Median age at diagnosis was 64 and 65, respectively, for low/high-
risk EC and 69 in the validation cohort. Patients from the initial
study cohort with high-risk EC presented more frequently with
unfavourable clinicopathological findings: advanced FIGO stage
(chi2¼ 53.0; df¼ 3; P¼ 0.000), deep myometrial invasion
(chi2¼ 22.2; df¼ 1; P¼ 0.000), LVSI (chi2¼ 42.3; df¼ 1;
P¼ 0.000) and positive lymph nodes (chi2¼ 4.9; df¼ 1;
P¼ 0.027), compared with those with low-risk EC. Patients with
high-risk EC were also more likely to receive adjuvant radiotherapy
(chi2¼ 19.6; df¼ 1; P¼ 0.000). Significantly, more patients
received adjuvant chemotherapy in the validation cohort compared
with high-risk patients in the study cohort. Immunological
findings in the initial study cohort show that a ratio of cytotoxic/
regulatory T-cells above the median was seen more often in low-
risk EC compared with high-risk EC (55.8% vs 38.5%, respectively
(chi2¼ 10.0; df¼ 1; P¼ 0.002). Memory T-cells were present in
62.3% of low-risk and 54.1% of high-risk EC (chi2¼ 3.7; df¼ 1;
P¼ 0.056). There was no significant difference in HLA class 1
expression or number of CTLs between low- and high-risk EC.





Figure 1. Examples of immunohistochemical staining for CD8 in high-
risk EC (A) tumour with low number of CTLs. (B) Tumour with high
numbers of CTLs.
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Table 1. Baseline characteristics of the initial study cohort stratified by low- and high-risk EC, and the high-risk validation cohort














Median age 64 IQ: 56–73 65 IQ: 56–73 chi2; df; P-value 69 IQ: 61–76
Treatment
Surgery 250 100.0 105 100.0 — 72 100.0
Adjuvant radiotherapy 127 50.8 80 76.2 19.6; 1; o0.001 42 56.8
Chemotherapy 5 2.0 4 3.8 1.0; 1; ¼ 0.332 13 17.6
FIGO 53.0; 3; o0.001
Stage 1 164 65.6 32 30.5 35 49.3
Stage 2 40 16.0 18 17.1 9 12.6
Stage 3 40 16.0 37 35.2 23 0.32
Stage 4 6 2.4 18 17.1 4 0.1
Missing 1
Invasion myometrium 22.2; 1; o0.001
ohalf 163 65.2 40 38.1 13 19.7
4half 87 34.8 65 61.9 53 80.3
Missing 6
Lymph nodes (any) 4.9; 1; ¼0.027
Negative 67 79.8 46 63.9 a a
Positive 17 20.2 26 36.1 9 12.7
Not assessed 166 33
Lymphovascular invasion 42.3; 1; o0.001
No 194 81.9 48 47.1 23 46.0
Yes 43 18.1 54 52.9 27 54.0
Missing 13 3 22
Differentiation grade 350.2; 3; o0.001
Grade 1 159 63.6 3 6.7
Grade 2 91 36.4 1 1.0 5 11.1
Grade 3 98 93.3 37 82.2
Undifferentiated 6 5.7
Missing 27
Tumour type 136.4; 3; o0.001
Endometrioid 250 100.0 56 53.4 45 68.1
Serous papillary 18 17.1 9 13.6
Clear cell 25 23.8 18 27.3
Undifferentiated 6 5.7 6
HLA class 1b 1.6; 1; ¼ 0.212
Normal expression 110 57.9 44 50.0 — —
Loss of expression 85 42.1 44 50.0 — —
Missing 48 17
Memory T cellsb 3.7; 1; ¼ 0.056
None 69 37.7 41 45.9 38 61.3
Present 130 62.3 47 54.1 24 38.7
Missing 51 17 12
CTLsb 0.6; 1; ¼ 0.423
Below median 100 48.0 48 50.7 38 63.3
Above median 112 52.0 44 49.3 22 39.7
Missing 38 13 12
Ratio cytotoxic/regulatory T cellsb 10,0; 1; ¼ 0.002
omedian 88 44.2 58 61.5 — —
4median 113 55.8 33 38.5 — —
Missing 49 14
Abreviations: CTLs¼ cytotoxic T cells; EC¼endometrial cancer; HLA¼ human leukocyte antigen. Percentages exclude missing values.
aData on the number of lymph node dissections performed in the validation cohort was unknown.
bValues before imputation. Relative efficiency of imputation was between 0.97 and 1.00.
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Survival is shown in Table 2. In the initial study cohort, disease
recurred in 32% of patients with high-risk EC and in 21% of
low-risk EC (chi2¼ 5.4; df¼ 1; P¼ 0.020). The location of
recurrence showed a similar pattern in both low- and high-risk
EC. Almost all patients with recurrence of high risk died during
follow-up. Overall, 44% of patients with high-risk EC died of
disease during follow-up vs 25% of patients with low-risk EC
(chi2¼ 16.9; df¼ 1; P¼ 0.000). For the validation cohort, clin-
icopathological and immunological findings as well as survival was
not significantly different from the high-risk subgroup from the
initial study cohort.
Backward selection of clinicopathological variables resulted in
FIGO stage and LVSI as independent predictors for DFS. In
backward selection of immunological variables, only high/low
numbers of CTLs remained significant. Analysis of both clinico-
pathological and immunological variables resulted in the presence
of memory cells, FIGO stage and LVSI as predictors for DFS. The
HR and discriminatory power for DFS of the selected variables for
the entire cohort are shown in Table 3. Disease-free survival is best
predicted by FIGO and LVSI combined (C-index 0.81). Addition of
either immunological variable (CTLs or memory cells) to this
combination did not improve the discriminatory power (C-index
0.83). The discriminatory power of either CTLs or memory T-cells
alone as a predictor of recurrence or death was low in the total
cohort (C-index of 0.60 and 0.61, respectively).
Results after stratification for low/high-risk EC are shown in
Table 4. In low risk, FIGO and LVSI were the best predictors for
DFS and addition of either CTLs or memory T cells did not
improve the discriminatory power. However, in high-risk EC, DFS
is best predicted by FIGO and LVSI combined with CTLs (Table 4,
C-index 0.79). A combination of clinicopathological variables with
the presence of memory T cells also performs well (C-index 0.76).
Separately, the discriminatory power of either immunological
variable was similar to that of FIGO and LVSI combined (C-index
of 0.71 vs 0.70).
C-index for the subgroups low- vs high-grade EC and
endometrioid vs non-endometrioid EC was similar to the combina-
tion of these subgroups in low- vs high-risk EC. In both high-grade
and non-endometrioid EC, DFS was best predicted by a combination
of FIGO and LVSI with CTLs (C-index 0.80 vs 0.85, respectively).
For comparison, DSS was also analysed and showed a similar
pattern (data not shown). In high-risk EC, clinicopathological
variables performed similarly to either CTLs or memory T cells
(C-index 0.63 vs 0.64–0.68). The combination of FIGO, LVSI and
CTLs had the highest predictive accuracy for survival (C-index
0.72). Both presence of memory T cells and low numbers of CTLs
contribute to the prediction of DSS (data not shown).
Table 5 shows HRs and the C-index for the validation cohort. The
discriminatory power of CTLs below/above the median in the
validation cohort equalled that of advanced FIGO stage and LVSI
combined (C-index 0.71). The combination increased the discrimina-
tory power (C-index 0.79) confirming the results of the initial study
cohort. Furthermore, findings in the subgroup analysis of low- vs high-
grade EC (C-index 0.84) and endometrioid vs non-endometrioid EC
(C-index 0.80) was similar to low- vs high-risk EC (data not shown).
Figure 2 represents DFS in the validation cohort and confirms
the finding in previous studies that a high number of CTLs is
related to a favourable disease course. Figure 3 is a boxplot
illustrating the distribution of CTLs for patients from the
validation cohort, with and without an event in DFS. There was
one recurrence out of 19 patients with a CTL count above 50.
Without imputation, and using only cases with all variables
complete, the datasets contained 257 and 54 cases for the study and
validation cohort, respectively. Results were similar to that of the
imputed dataset. Cytotoxic T cells performed well as a predictor for
regional and distant recurrence in the high-risk study cohort and the
validation cohort (C-index 0.71 and 0.74, respectively). Combination
with FIGO stage and LVSI again increased the predictive power with
a C-index of 0.80 in the high-risk study cohort and 0.83 in the
validation cohort.
Table 2. Disease outcome in 355 patients with EC stratified by low- and high-risk EC, and the high-risk validation cohort
Low risk (n¼250) High risk (n¼105) Difference betweenlow and high risk Validation cohort (n¼74)
Number % Number % chi2; df; P-value Number %
Recurrent disease 52 34 5.4; 1; ¼0.02 37
Local 21 40.4 9 26.5
Regional 6 11.5 5 14.7 9 24.3
Distant 25 48.1 20 58.8 24 64.9
Missing 4
Death 62 46 18,0; 2; o0.001
Death of disease 29 46.8 31 67.4 22 78.9
Death of other disease 33 53.2 15 32.6 6 21.4
Missing 3
Total 62 46 31
Abbreviation: EC¼ endometrial cancer. Percentages exclude missing values.
Table 3. Hazard ratios and discriminatory power (C-index) for disease-free survival in the original cohort (n¼355)
HR (95% CI) C-index
FIGO, LVSI 4.5 (3.3–6.3), 4.4 (3.4–5–8) 0.81
CTLs 0.35 (0.27–0.46) 0.60
Memory T-cells 0.44 (0.34–0.57) 0.61
FIGO, LVSI, CTLs 4.1 (3.0–5.8), 4.5 (3.4–5.9), 0.41 (0.32–0.53) 0.83
FIGO, LVSI, memory T cells 4.2 (3.0–5.8), 4.9 (3.7–6.4), 0.39 (0.30–0.50) 0.83
Abbreviations: CI¼ confidence interval; CTLs¼ cytotoxic T cells; HR¼ hazard ratio; FIGO¼FIGO disease classification 1988, LVSI¼ lymphovascular invasion.
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DISCUSSION
Immunological parameters may be useful to select patients with
high-risk EC for adjuvant therapy. Low numbers of CTLs is
equivalent to FIGO stage and LVSI combined for predicting
regional and distant recurrence or death from disease in type 2 EC.
A model that combines all three parameters has the highest
predictive power in high-risk EC.
Currently, the selection of patients for adjuvant treatment
depends on age, depth of myometrial invasion and histological
subtype (Creutzberg et al, 2000; ASTEC study group et al, 2009;
Nout et al, 2010; Kong et al, 2012). Our data support the role of
FIGO stage and LVSI in decision-making. Age was not selected in
backward selection and we therefore cannot confirm the role of age
in decision-making. Cytotoxic T cells could contribute to decision-
making in order to reduce the number of patients receiving
adjuvant treatment while at the adjuvant radiotherapy with its
associated toxicity, whilst at the same time keeping the risk of
recurrence as low as possible. Furthermore, a model that accurately
predicts distant recurrence could indicate which patient should
additionally receive adjuvant chemotherapy, rather than radio-
therapy alone.
In theory, a high discriminatory power of CTLs and memory T
cells could be explained by the involvement of immune system in
the development and progression of cancer. The immune system
can eliminate tumours by killing of cancer cells (Schreiber et al,
2011; Vesely et al, 2011). However, in doing so, a selection of
tumour cells will survive by escaping immune surveillance. The
presence of memory and especially CTLs may reflect a functional
immune response capable of eradication of tumour cells. This
immune response consists of a chain of events from antigen
presentation and recognition to tumour infiltration and destruc-
tion of cancer cells. Tumour infiltration by CTLs and memory
T cells indicates that previous steps in the immune response were
successful.
Predicting recurrence using immunological variables is a
relatively new concept. In colorectal cancer, an immunological
prediction model has shown promising results (Galon et al,
Table 4. Hazard ratios and discriminatory power (C-index) for disease-free survival, stratified by low- and high-risk EC
Low risk (n¼250) High risk (n¼105)
HR (95% CI) C-index HR (95% CI) C-index
FIGO, LVSI 5.1 (3.5–7.6), 8.0 (5.6–11.3) 0.85 3.8 (2.0–7.0), 2.0 (1.3–3.0) 0.70
CTLs 0.61 (0.43–0.86) 0.52 0.23 (0.15–0.37) 0.67
Memory T cells 0.90 (0.85–0.96) 0.59 0.75 (0.66–0.84) 0.71
FIGO, LVSI, CTLs 5.1 (3.4–7.5), 8.1 (5.7–11.5), 1.2 (0.79–1.7) 0.86 3.2 (1.7–5.9), 2.0 (1.3–3.1), 0.29 (0.19–0.45) 0.79
FIGO, LVSI, memory T cells 4.4 (2.9–6.7), 7.5 (5.1–11.1), 1.2 (0.86–1.7) 0.87 1.7 (0.9–3.3), 2.9 (1.8–4.6), 0.73 (0.64–0.83) 0.76
Abbreviations: CI¼ confidence interval; CTLs¼ cytotoxic T cells; HR¼ hazard ratio; FIGO¼FIGO disease classification 1988, LVSI¼ lymphovascular invasion.
Table 5. Hazard ratios and predictive value (C-index) for disease-free survival in the high-risk validation cohort (n¼72)
HR (95% CI) C-index
FIGO, LVSI 3.02 (2.23–4.01); 1.00 (1.00–1.00) 0.71
CTLs 0.16 (0.11–0.24) 0.71
Memory T cells 0.42 (0.30–0.59) 0.61
FIGO, LVSI, CTLs 2.51 (1.83–3.45); 1.00 (1.00–1.00); 0.17 (0.12–0.25) 0.79
FIGO, LVSI, memory T cell 2.96 (2.17–4.05); 1.00 (1.00–1.00); 0.42 (0.29–0.60) 0.74






















Figure 2. Kaplan–Meier curve showing DFS for tumour-infiltrating



























Figure 3. Number of tumour-infiltrating CTLs for patients with and
without recurrence for 72 patients in the validation cohort.
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2006; Pages et al, 2009; Bindea et al, 2011; Fridman et al, 2011;
Mlecnik et al, 2011). A score derived from number of intra-
tumoural cytotoxic and memory T cells had a concordance index
of 0.65 for DFS and 0.66 for DSS in colorectal cancer, which was
higher than that of TNM classification. To our knowledge, we are
the first to explore the possibility of an immune prediction score
for recurrence in EC. Similarly to what has been shown in
colorectal cancer, CTLs and, to a lesser extent, memory T cells are
the best predictors for recurrence in our study. We used the
median number of cytotoxic cells per core as the cut-off for
distinguishing low and high CTL density, as was previously
described by Galon et al (2006) in colorectal cancer (Pages et al,
2009; Bindea et al, 2011; Fridman et al, 2011; Mlecnik et al, 2011).
However, this cut-off is arbitrary and may not be the optimal
threshold for predicting disease recurrence. With a higher cut-off
point, discriminatory power for no recurrence will increase. The
boxplot (Figure 3) shows that there were only a few recurrences for
patients with a high CTL count. In fact, there was only one
recurrence in the 21 cases with a count above 50. Of these 21
patients, 18 had an indication for adjuvant radiotherapy. These
data do exemplify that patients with a high number of CTLs may
be better off without adjuvant radiotherapy. Future studies are
needed to determine the optimal threshold.
We specifically evaluated TIL and HLA-class 1 expression as
possible predictors in EC. Other immunological variables such as
PD1 were not evaluated but may also contribute in patient selection.
We performed immunofluorescent staining for PD1 in sections of
EC as part of another study but were unable to confirm a relation to
survival. Nonetheless, it might be useful to examine a possible
contribution of other immunological variables in patient selection.
Radiotherapy reduces local recurrence and is advised for
patients with a high-risk profile based on clinicopathological
variables, and this could be a confounding factor in our study. As
patients in our cohorts were treated accordingly, fewer local
recurrences were seen, as expected, in those patients who received
radiotherapy. We therefore excluded local recurrence when
defining DFS. We are aware that this may cause a selection bias
if local recurrence is related to distant recurrence. Future work
should include similar cohorts of patients treated in randomised
trials of radiotherapy and/or adjuvant chemotherapy.
Here, we describe an innovative statistical approach to
establish which immunological predictors can select patients for
adjuvant treatment. A multivariate Cox regression analysis
was used to select relevant predictors from a pool of candidate
predictors. This analysis also provides the relative risk
of recurrence in HRs, but gives no information on how well
a variable or combination of variables can discriminate between
recurrence or no recurrence. The discriminatory power of selected
clinicopathological and immunological variables was assessed
by calculating a C-index, where a C-index close to 1 is indicative
of a strong discrimination between recurrence and no recurrence,
and the resultant C-index can also be used to determine the quality
of a model.
There are several issues to address in the statistical approach.
For example, missing data can be problematic in developing a
model and several methods have been described to deal with
missing values (Royston et al, 2009). In this study, we choose to
impute for missing values because of limitations caused by
alternative approaches. The high relative efficiency in our
imputation (0.97–1.00) suggests a high concordance between the
five imputations. Alternatively, missing values could be ignored or
deleted. However, this would result in the loss of significance and
possibly to incorrect estimates of discriminatory power. Also, in
our approach, the best predictors were selected by first including all
variables and then selecting the best model using backward
selection. The advantage of this approach is that the information of
the correlation structure between the variables is used in the
selection of variables. Another possibility would have been to select
the most significant variables from univariate analysis and take
these forward into the multivariate analysis. However, selecting
variables by significance testing allows for a selection bias and over
fitting of a model. Furthermore, including all variables may result
in an impractical model (Royston et al, 2009).
We used as our initial study cohort a large, consecutive case
series previously described and subsequently updated to include up
to 6 years of follow-up (de Jong et al, 2009; Bijen et al, 2010). Two
studies have already described a relationship between immun-
ological variables and disease course. Over fitting may occur when
these variables are subsequently tested for prediction of recurrence.
Results were therefore tested in an independent, international
validation cohort of patients collected in the TransPORTEC
collaboration with high-risk EC. Clinicopathological findings in
this cohort were similar to the study cohort except for a lower
number of patients receiving adjuvant chemotherapy in the latter.
Possibly, this reflects an international difference in pattern of care
between institutions. The validation cohort confirms the findings
from our initial study cohort and agrees with previously published
studies in EC (Kondratiev et al, 2004; Chang et al, 2005; de Jong
et al, 2009; Gooden et al, 2011). Presence of memory T cells and
high numbers of CTLs in the tumour relates to DFS and DSS. The
discriminatory power of high/low numbers of CTLs was similar in
both the study and validation cohorts.
In conclusion, here, we describe for the first time a prospective
statistical approach to select immunological variables as predictors
of recurrence in EC. In high-risk EC, recurrence was best predicted
by a combination of FIGO stage and LVSI in addition to cytotoxic
or memory T-cell numbers. The discriminatory power of
both cytotoxic and memory T cells should be confirmed in a
larger cohort, preferably from a randomised controlled trial of
high-risk EC.
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